{"id":35193,"date":"2025-06-13T15:51:18","date_gmt":"2025-06-13T07:51:18","guid":{"rendered":"https:\/\/flcube.com\/?p=35193"},"modified":"2025-06-13T15:51:19","modified_gmt":"2025-06-13T07:51:19","slug":"gsk-licenses-shigella-vaccine-to-bharat-biotech-for-low-and-middle-income-countries","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35193","title":{"rendered":"GSK Licenses Shigella Vaccine to Bharat Biotech for Low- and Middle-Income Countries"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">UK-based GSK plc (<a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE: GSK<\/a>) announced a licensing agreement with Bharat Biotech International Limited, an Indian multinational biotech company. This agreement permits Bharat Biotech to continue developing and potentially distributing its Shigella vaccine candidate, altSonflex1-2-3, in low- and middle-income countries. This collaboration addresses the significant health burden of Shigella, a leading bacterial cause of diarrhea, particularly threatening children under five in these regions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Vaccine Technology<\/strong><br>The vaccine leverages innovative GMMA technology (Generalized Modules for Membrane Antigens), utilizing naturally released outer membrane vesicles (OMVs) from bacteria. These OMVs deliver antigens that activate the immune system, typically without the need for adjuvants. This technology offers a flexible approach to combatting multiple bacterial diseases, including Shigella.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Clinical Trial Results<\/strong><br>Phase I clinical trials and interim analyses from Phase II studies have demonstrated promising results. The vaccine has met predefined immunogenicity success criteria, indicating its potential to provide effective protection against Shigella infections.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/gsk-licenses-shigella-vaccine-candidate-to-bharat-biotech_12-june-2025.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of gsk-licenses-shigella-vaccine-candidate-to-bharat-biotech_12-june-2025.\"><\/object><a id=\"wp-block-file--media-6e7ab8bb-2025-4595-bd22-c7ad9c96765d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/gsk-licenses-shigella-vaccine-candidate-to-bharat-biotech_12-june-2025.pdf\">gsk-licenses-shigella-vaccine-candidate-to-bharat-biotech_12-june-2025<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/gsk-licenses-shigella-vaccine-candidate-to-bharat-biotech_12-june-2025.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6e7ab8bb-2025-4595-bd22-c7ad9c96765d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>UK-based GSK plc (NYSE: GSK) announced a licensing agreement with Bharat Biotech International Limited, an&#8230;<\/p>\n","protected":false},"author":1,"featured_media":35196,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4150,184,914,12],"class_list":["post-35193","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-bharat-biotech","tag-gsk","tag-nyse-gsk","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK Licenses Shigella Vaccine to Bharat Biotech for Low- and Middle-Income Countries - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK-based GSK plc (NYSE: GSK) announced a licensing agreement with Bharat Biotech International Limited, an Indian multinational biotech company. This agreement permits Bharat Biotech to continue developing and potentially distributing its Shigella vaccine candidate, altSonflex1-2-3, in low- and middle-income countries. This collaboration addresses the significant health burden of Shigella, a leading bacterial cause of diarrhea, particularly threatening children under five in these regions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35193\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK Licenses Shigella Vaccine to Bharat Biotech for Low- and Middle-Income Countries\" \/>\n<meta property=\"og:description\" content=\"UK-based GSK plc (NYSE: GSK) announced a licensing agreement with Bharat Biotech International Limited, an Indian multinational biotech company. This agreement permits Bharat Biotech to continue developing and potentially distributing its Shigella vaccine candidate, altSonflex1-2-3, in low- and middle-income countries. This collaboration addresses the significant health burden of Shigella, a leading bacterial cause of diarrhea, particularly threatening children under five in these regions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35193\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-13T07:51:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-13T07:51:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1308.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35193#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35193\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK Licenses Shigella Vaccine to Bharat Biotech for Low- and Middle-Income Countries\",\"datePublished\":\"2025-06-13T07:51:18+00:00\",\"dateModified\":\"2025-06-13T07:51:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35193\"},\"wordCount\":170,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35193#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1308.webp\",\"keywords\":[\"Bharat Biotech\",\"GSK\",\"NYSE: GSK\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35193#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35193\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35193\",\"name\":\"GSK Licenses Shigella Vaccine to Bharat Biotech for Low- and Middle-Income Countries - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35193#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35193#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1308.webp\",\"datePublished\":\"2025-06-13T07:51:18+00:00\",\"dateModified\":\"2025-06-13T07:51:19+00:00\",\"description\":\"UK-based GSK plc (NYSE: GSK) announced a licensing agreement with Bharat Biotech International Limited, an Indian multinational biotech company. This agreement permits Bharat Biotech to continue developing and potentially distributing its Shigella vaccine candidate, altSonflex1-2-3, in low- and middle-income countries. This collaboration addresses the significant health burden of Shigella, a leading bacterial cause of diarrhea, particularly threatening children under five in these regions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35193#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35193\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35193#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1308.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1308.webp\",\"width\":1080,\"height\":608,\"caption\":\"GSK Licenses Shigella Vaccine to Bharat Biotech for Low- and Middle-Income Countries\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35193#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK Licenses Shigella Vaccine to Bharat Biotech for Low- and Middle-Income Countries\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK Licenses Shigella Vaccine to Bharat Biotech for Low- and Middle-Income Countries - Insight, China&#039;s Pharmaceutical Industry","description":"UK-based GSK plc (NYSE: GSK) announced a licensing agreement with Bharat Biotech International Limited, an Indian multinational biotech company. This agreement permits Bharat Biotech to continue developing and potentially distributing its Shigella vaccine candidate, altSonflex1-2-3, in low- and middle-income countries. This collaboration addresses the significant health burden of Shigella, a leading bacterial cause of diarrhea, particularly threatening children under five in these regions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35193","og_locale":"en_US","og_type":"article","og_title":"GSK Licenses Shigella Vaccine to Bharat Biotech for Low- and Middle-Income Countries","og_description":"UK-based GSK plc (NYSE: GSK) announced a licensing agreement with Bharat Biotech International Limited, an Indian multinational biotech company. This agreement permits Bharat Biotech to continue developing and potentially distributing its Shigella vaccine candidate, altSonflex1-2-3, in low- and middle-income countries. This collaboration addresses the significant health burden of Shigella, a leading bacterial cause of diarrhea, particularly threatening children under five in these regions.","og_url":"https:\/\/flcube.com\/?p=35193","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-13T07:51:18+00:00","article_modified_time":"2025-06-13T07:51:19+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1308.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35193#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35193"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK Licenses Shigella Vaccine to Bharat Biotech for Low- and Middle-Income Countries","datePublished":"2025-06-13T07:51:18+00:00","dateModified":"2025-06-13T07:51:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35193"},"wordCount":170,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35193#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1308.webp","keywords":["Bharat Biotech","GSK","NYSE: GSK","Vaccine"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35193#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35193","url":"https:\/\/flcube.com\/?p=35193","name":"GSK Licenses Shigella Vaccine to Bharat Biotech for Low- and Middle-Income Countries - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35193#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35193#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1308.webp","datePublished":"2025-06-13T07:51:18+00:00","dateModified":"2025-06-13T07:51:19+00:00","description":"UK-based GSK plc (NYSE: GSK) announced a licensing agreement with Bharat Biotech International Limited, an Indian multinational biotech company. This agreement permits Bharat Biotech to continue developing and potentially distributing its Shigella vaccine candidate, altSonflex1-2-3, in low- and middle-income countries. This collaboration addresses the significant health burden of Shigella, a leading bacterial cause of diarrhea, particularly threatening children under five in these regions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35193#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35193"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35193#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1308.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1308.webp","width":1080,"height":608,"caption":"GSK Licenses Shigella Vaccine to Bharat Biotech for Low- and Middle-Income Countries"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35193#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK Licenses Shigella Vaccine to Bharat Biotech for Low- and Middle-Income Countries"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1308.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35193"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35193\/revisions"}],"predecessor-version":[{"id":35197,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35193\/revisions\/35197"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35196"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}